Key facts
- It has raised $620K; the latest was Seed Round ($100K) in Feb 2026.
- Notable investors include Virginia Innovation Partnership Corporation, Regional Accelerator & Mentoring Program, VT Corporate Research Center.
- Qentoros has filed 1 Form D with the SEC, most recently Feb 2026 ($100K sold to 2 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Qentoros
- ·The full record, as it builds
Funding rounds
No funding rounds for Qentoros are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qentoros
Developer of a biological treatment intended to alleviate many infectious and inflammatory conditions in animals and humans. The company facilitates the creation of therapeutics from platelet-rich plasma or PRP formulation, enabling people to promote a healthy immune response, dampen overzealous inflammation, and stimulate tissue regeneration.
- Sector
- Business Products and Services (B2B)
- HQ
- Blacksburg, VA, United States
- Founded
- 2022
- Employees
- 9
- Website
- qentoros.com/
- Ownership
- Privately Held (backing)
Qentoros doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qentoros shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qentoros in its N-PORT filings yet. We sweep new filings monthly.